发明名称 TREATMENT OF DEPRESSION SECONDARY TO PAIN (DSP)
摘要 Methods for the prevention or treatment of atypical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine re uptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amou nt of a dual serotonin norepinephrine reuptake inhibitor (SRNI) compound of a specific type, or a pharmaceutically acceptable sait thereof is administered . The most preferred SNRI compounds are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compound is milnacipran or a bioequivalent or pharmaceutically acceptable sait thereof. Other preferred compounds are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amount of a non-tricyclic triple reuptake inhibito r ("TRI") compound of a specific type, or a pharmaceutically acceptable sait thereof, is administered. The TRI compounds are characterized by their abili ty to block the reuptake (and, hence, increase central concentrations of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.</SDO AB>
申请公布号 CA2493490(A1) 申请公布日期 2004.01.29
申请号 CA20032493490 申请日期 2003.07.24
申请人 CYPRESS BIOSCIENCE, INC. 发明人 RAO, SRINIVAS G.;KRANZLER, JAY D.
分类号 A61K31/131;A61K31/135;A61K31/165;(IPC1-7):A61K31/165 主分类号 A61K31/131
代理机构 代理人
主权项
地址